⌘K
Loading ticker…
As of 2026-08-25, Xenetic Biosciences, Inc. (XBIO) has a 3-month relative strength percentile of 84 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 62. The current market Stance is 52.9 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 7.3%, relative volume 0.38×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
XBIO appears in 1 ETF as of Mar 2026: VXF at 0.00% weight, $18K notional.
Held by 1 ETFs · $18K across latest filings · largest weight 0.00% (VXF).
Top 1 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VXFVanguard Extended Market ETF | 0.00% | $18K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | XBIO Jan avg: 42.93% median: 8.37% win: 100% σ: 73.20% n: 4 2022-04-12 → 2026-07-31 | XBIO Feb avg: -3.12% median: 0.68% win: 50% σ: 19.32% n: 4 2022-04-12 → 2026-07-31 | XBIO Mar avg: -14.60% median: -15.45% win: 25% σ: 16.94% n: 4 2022-04-12 → 2026-07-31 | XBIO Apr avg: 1.58% median: 8.81% win: 80% σ: 18.95% n: 5 2022-04-12 → 2026-07-31 | XBIO May avg: -4.34% median: 3.96% win: 60% σ: 15.20% n: 5 2022-04-12 → 2026-07-31 | XBIO Jun avg: 7.60% median: 4.36% win: 80% σ: 14.37% n: 5 2022-04-12 → 2026-07-31 | XBIO Jul avg: 1.42% median: 5.41% win: 60% σ: 15.89% n: 5 2022-04-12 → 2026-07-31 | XBIO Aug avg: -7.46% median: -8.35% win: 25% σ: 8.51% n: 4 2022-04-12 → 2026-07-31 (current) | XBIO Sep avg: 2.17% median: 7.90% win: 75% σ: 22.13% n: 4 2022-04-12 → 2026-07-31 | XBIO Oct avg: -12.23% median: -9.07% win: 25% σ: 18.38% n: 4 2022-04-12 → 2026-07-31 | XBIO Nov avg: -4.20% median: -0.94% win: 50% σ: 12.62% n: 4 2022-04-12 → 2026-07-31 | XBIO Dec avg: -13.42% median: -11.91% win: 25% σ: 17.26% n: 4 2022-04-12 → 2026-07-31 |